Precision Biologics to Reveal Preclinical Efficacy of Novel Tumor-Specific ADC against multiple human cancer types at SITC 2025
PR Newswire —
BETHESDA, Md., Nov. 5, 2025 /PRNewswire/ -- Precision Biologics, Inc. announces in vitro and in vivo efficacy of its novel tumor-specific ADC (PB-vcMMAE-5) against human carcinomas expressing truncated core 2 O-glycans. Recent data for several human cancer types expressing truncated core...